MeiraGTx Holdings plc Employee Count
The employee counts MeiraGTx Holdings plc states in its annual reports on SEC EDGAR, each as filed.
- 2025-12-31: Employees (as filed) 403; Filing 2026-03-30; Lease expense per employee $16,339.95.
- 2024-12-31: Employees (as filed) 381; Filing 2025-03-13; Lease expense per employee $18,023.62.
- 2023-12-31: Employees (as filed) 425; Filing 2024-03-15; Lease expense per employee $15,896.47.
- 2022-12-31: Employees (as filed) 358; Filing 2023-03-14; Lease expense per employee $18,337.99.
- Available history
- 2019-12-31 to 2025-12-31
Historical Employee Count
| Date | Employees (as filed) | Filing | Lease expense per employee |
|---|---|---|---|
| 2025-12-31 | 403 full-time | 2026-03-30 | $16,339.95 total lease cost |
| 2024-12-31 | 381 full-time | 2025-03-13 | $18,023.62 total lease cost |
| 2023-12-31 | 425 full-time | 2024-03-15 | $15,896.47 total lease cost |
| 2022-12-31 | 358 full-time | 2023-03-14 | $18,337.99 total lease cost |
| 2021-12-31 | 296 full-time | 2022-03-10 | $23,587.84 total lease cost |
| 2020-12-31 | 219 full-time | 2021-03-11 | $21,273.97 total lease cost |
| 2019-12-31 | 157 full-time | 2020-03-11 | $25,282.77 total lease cost |
Headcount breakdown as filed
| Fiscal year end | Employees | Xbrl:Range | Xbrl:StatementScenario | Filing |
|---|---|---|---|---|
| 2024-12-31 | 381 full-time | Maximum: 500 | SmallAndMediumSizedEnterpriseProgram: 500 | 2025-03-13 “As of December 31, 2024, we had 381 employees, 375 of which are full-time employees.” |
| 2023-12-31 | 425 full-time | Maximum: 500 | SmallAndMediumSizedEnterpriseProgram: 500 | 2024-03-15 “As of December 31, 2023, we had 425 employees, 419 of which are full-time employees.” |
| 2022-12-31 | 358 full-time | Maximum: 500 | SmallAndMediumSizedEnterpriseProgram: 500 | 2023-03-14 “As of December 31, 2022, we had 358 employees, 343 of which are full-time employees.” |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |